These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 11227615)

  • 1. ACE inhibitor reduces cardiovascular events by 22%.
    Indian J Med Sci; 2000 Mar; 54(3):112-4. PubMed ID: 11227615
    [No Abstract]   [Full Text] [Related]  

  • 2. A Step Ahead in Secondary Prevention of Cardiovascular Risk. Consensus Document on Clinical Use of the Polypill.
    González-Juanatey JR; Mostaza JM; Lobos JM; Abarca B; Llisterri JL
    Rev Esp Cardiol (Engl Ed); 2016 Jun; 69(6):547-50. PubMed ID: 27062678
    [No Abstract]   [Full Text] [Related]  

  • 3. Adding ACE inhibitors or ARBs to standard therapy for stable ischemic heart disease.
    Guirguis-Blake J
    Am Fam Physician; 2012 Jul; 86(1):21-3. PubMed ID: 22962909
    [No Abstract]   [Full Text] [Related]  

  • 4. Effect of ramipril on cardiovascular events in high-risk patients.
    Weinsaft JW
    N Engl J Med; 2000 Jul; 343(1):64; author reply 66. PubMed ID: 10896543
    [No Abstract]   [Full Text] [Related]  

  • 5. Randomisation in the SYMPHONY trial.
    Altman DG
    Lancet; 2000 Oct; 356(9240):1521-2. PubMed ID: 11081555
    [No Abstract]   [Full Text] [Related]  

  • 6. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials.
    Teo K; Yusuf S; Sleight P; Anderson C; Mookadam F; Ramos B; Hilbrich L; Pogue J; Schumacher H;
    Am Heart J; 2004 Jul; 148(1):52-61. PubMed ID: 15215792
    [TBL] [Abstract][Full Text] [Related]  

  • 7. What is the relevance of the HOPE study in general practice?
    Kennedy J; Mogensen CE; Ball SG; Castaigne AD; Commerford PJ; Distiller L; Fisher BM; Gonzalez-Jaunatey J; Nosadini R; Novials A; Ostergren J; Palma-Gámiz J; Perrone-Filardi P; Schipperheijn JJ; Senges J; Trevisan R
    Int J Clin Pract; 2001 Sep; 55(7):449-57. PubMed ID: 11594254
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Efficacy of angiotensin-converting enzyme inhibitors in secondary prevention].
    Ceconi C; Mastrorilli F; Squasi PA; Gaitani S; Guardigli G; Ferrari R
    Ital Heart J; 2005 Nov; 6 Suppl 7():5S-13S. PubMed ID: 16485512
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Heart Outcomes Prevention Evaluation study: angiotensin-converting enzyme inhibitors: are their benefits a class effect or do individual agents differ?
    Sica DA
    Curr Opin Nephrol Hypertens; 2001 Sep; 10(5):597-601. PubMed ID: 11496052
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ONTARGET proves telmisartan efficacy compared to ramipril in cardiovascular protection of patients at high risk and without heart failure.
    Cardiovasc J Afr; 2008; 19(2):108-9; discussion 109-10. PubMed ID: 18516357
    [No Abstract]   [Full Text] [Related]  

  • 11. HOPE for cardiovascular disease prevention with ACE-inhibitor ramipril. Heart Outcomes Prevention Evaluation.
    Kleinert S
    Lancet; 1999 Sep; 354(9181):841. PubMed ID: 10485736
    [No Abstract]   [Full Text] [Related]  

  • 12. [ONTARGET, PROFESS, TRANSCEND large scale studies. AT1 blockers: evidence based advantage, but less than expected].
    Einecke D
    MMW Fortschr Med; 2008 Sep; 150(38):14, 16. PubMed ID: 18983047
    [No Abstract]   [Full Text] [Related]  

  • 13. Study at up to 700 sites will build on landmark HOPE trial.
    Cardiovasc J S Afr; 2001; 12(2):127-30. PubMed ID: 11474703
    [No Abstract]   [Full Text] [Related]  

  • 14. [Vascular patient with high infarction risk. Does the AT-1 blocker protect as well as an ACE inhibitor?].
    MMW Fortschr Med; 2003 Dec; 145(51-52):39. PubMed ID: 14974331
    [No Abstract]   [Full Text] [Related]  

  • 15. Ramipril in the treatment of vascular diseases.
    Rokoss MJ; Teo KK
    Expert Opin Pharmacother; 2005 Sep; 6(11):1911-9. PubMed ID: 16144510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lessons learned from a clinical trial.
    Armstrong PW; Newby LK; Granger CB; Lee KL; Simes RJ; Van de Werf F; White HD; Califf RM;
    Circulation; 2004 Dec; 110(23):3610-4. PubMed ID: 15583090
    [No Abstract]   [Full Text] [Related]  

  • 17. Ramipril for the prevention and treatment of cardiovascular disease.
    Vuong AD; Annis LG
    Ann Pharmacother; 2003 Mar; 37(3):412-9. PubMed ID: 12639174
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ACE inhibitors to prevent cardiovascular events in high-risk patients.
    VandeKieft GK
    J Fam Pract; 2000 Apr; 49(4):373-4. PubMed ID: 10778846
    [No Abstract]   [Full Text] [Related]  

  • 19. Differential antiplatelet effects of angiotensin converting enzyme inhibitors: comparison of ex vivo platelet aggregation in cardiovascular patients with ramipril, captopril and enalapril.
    Skowasch D; Viktor A; Schneider-Schmitt M; Lüderitz B; Nickenig G; Bauriedel G
    Clin Res Cardiol; 2006 Apr; 95(4):212-6. PubMed ID: 16598590
    [TBL] [Abstract][Full Text] [Related]  

  • 20. From the HOPE to the ONTARGET and the TRANSCEND studies: challenges in improving prognosis.
    Yusuf S
    Am J Cardiol; 2002 Jan; 89(2A):18A-25A; discussion 25A-26A. PubMed ID: 11835907
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.